Metrics as of 10/13/2026, 06:38 PM (Berlin time), refresh in progress.
Braveheart Bio, Inc.
Braveheart Bio, Inc. is a healthcare company operating within the biotechnology industry and is headquartered in San Francisco, US. The company engages in the development of therapeutics specifically designed to treat hypertrophic cardiomyopathy. Its primary focus lies on its lead product candidate known as BHB-1839,…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
1D
+1.2%
1W
+5.3%
1M
-27.6%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
PRICE TARGET LOW
US$40.00
CONSENSUS
US$45.25
MEDIAN
US$46.50
PRICE TARGET HIGH
US$48.00
No current analyst ratings available.
FREE FLOAT
–
FLOAT SHARES
–
AVG. DAILY VOLUME (30D)
534,060
AH Bio Fund IV, L.P.
ORBIMED ADVISORS LLC
ORBIMED ADVISORS LLC
ORBIMED ADVISORS LLC
Chimovits Erez
Braveheart Bio, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Travis Murdoch, the company employs around 49 people.
The IPO was on 06/08/2026; the stock trades on NASDAQ under the ticker BRVE.
The average price target is US$45.25, ranging from US$40.00 to US$48.00, with a median of US$46.50.
This is an external assessment, not a statement by Market Jury.
No, Braveheart Bio currently does not pay a dividend.
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
Clicking "Analyze stock" lets five strategies assess Braveheart Bio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.